Dolutegravir + Lamivudine Is Non‑Inferior to Bictegravir/FTC/TAF for Maintenance Therapy at 48 Weeks: PASO‑DOBLE Randomised Trial
Highlight
– In the PASO‑DOBLE multicentre Spanish trial, dolutegravir 50 mg plus lamivudine 300 mg (DTG/3TC) was non‑inferior to bictegravir 50 mg/emtricitabine 200 mg/tenofovir alafenamide 25 mg (BIC/FTC/TAF) for maintenance of virological suppression at 48 weeks (non‑inferiority margin 4%).
– Virological failure was rare in both arms (2% DTG/3TC vs 1% BIC/FTC/TAF) and trial discontinuations for adverse events were uncommon.
MedXY registered readers
Sign in free to continue reading
Create or use your MedXY account to unlock the complete article.
This article was created using several editorial tools, including AI, as part of the process. Human editors reviewed this content before publication.